- Home
- ARMK vs CORT Comparison
ARMK vs CORT Comparison
Compare ARMK & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMK
- CORT
- Stock Information
- Founded
- ARMK 1959
- CORT 1998
- Country
- ARMK United States
- CORT United States
- Employees
- ARMK N/A
- CORT N/A
- Industry
- ARMK Restaurants
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- ARMK Consumer Discretionary
- CORT Health Care
- Exchange
- ARMK Nasdaq
- CORT Nasdaq
- Market Cap
- ARMK 10.1B
- CORT 8.8B
- IPO Year
- ARMK 2013
- CORT N/A
- Fundamental
- Price
- ARMK $38.65
- CORT $78.82
- Analyst Decision
- ARMK Strong Buy
- CORT Strong Buy
- Analyst Count
- ARMK 10
- CORT 4
- Target Price
- ARMK $45.20
- CORT $139.00
- AVG Volume (30 Days)
- ARMK 2.3M
- CORT 969.1K
- Earning Date
- ARMK 11-10-2025
- CORT 10-29-2025
- Dividend Yield
- ARMK 1.08%
- CORT N/A
- EPS Growth
- ARMK 3.13
- CORT N/A
- EPS
- ARMK 1.36
- CORT 1.11
- Revenue
- ARMK $17,874,782,000.00
- CORT $716,080,000.00
- Revenue This Year
- ARMK $9.19
- CORT $30.77
- Revenue Next Year
- ARMK $5.76
- CORT $37.75
- P/E Ratio
- ARMK $28.52
- CORT $70.60
- Revenue Growth
- ARMK 4.02
- CORT 25.71
- 52 Week Low
- ARMK $29.92
- CORT $42.01
- 52 Week High
- ARMK $44.49
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- ARMK 47.37
- CORT 48.94
- Support Level
- ARMK $38.26
- CORT $69.43
- Resistance Level
- ARMK $40.30
- CORT $80.40
- Average True Range (ATR)
- ARMK 0.92
- CORT 4.33
- MACD
- ARMK 0.07
- CORT -1.33
- Stochastic Oscillator
- ARMK 26.76
- CORT 43.53
About ARMK Aramark
Aramark, founded in 1936 and headquartered in Philadelphia, Pennsylvania, operates as a food service company providing facility management and workplace solutions. The company primarily generates revenue from its North American food and support services segment, serving various clients including schools, healthcare facilities, and entertainment venues.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.